Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Clinical trial NCT03067571 · TERMINATED
Trial details
- NCT number
- NCT03067571
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-27
- Primary completion
- 2022-11-21
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.